Avantor, Inc. (AVTR)
| Market Cap | 10.13B +15.8% |
| Revenue (ttm) | 6.56B -1.6% |
| Net Income | -578.00M |
| EPS | -0.85 |
| Shares Out | 676.36M |
| PE Ratio | n/a |
| Forward PE | 17.36 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,654,019 |
| Open | 15.13 |
| Previous Close | 15.19 |
| Day's Range | 14.85 - 15.18 |
| 52-Week Range | 7.27 - 15.93 |
| Beta | 0.89 |
| Analysts | Hold |
| Price Target | 14.56 (-2.74%) |
| Earnings Date | Jul 29, 2026 |
About AVTR
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education an... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for AVTR stock is "Hold." The 12-month stock price target is $14.56, which is a decrease of -2.74% from the latest price.
News
Avantor price target raised to $14 from $10 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Avantor (AVTR) to $14 from $10 and keeps an Equal Weight rating on the shares. The firm updated its model for Avantor…
Avantor price target raised to $14 from $9 at RBC Capital
RBC Capital analyst Dan Leonard raised the firm’s price target on Avantor (AVTR) to $14 from $9 and keeps a Sector Perform rating on the shares after its Q2 earnings…
Avantor price target raised to $12 from $8 at JPMorgan
JPMorgan raised the firm’s price target on Avantor (AVTR) to $12 from $8 and keeps a Neutral rating on the shares.
Avantor price target raised to $14 from $10.50 at Evercore ISI
Evercore ISI raised the firm’s price target on Avantor (AVTR) to $14 from $10.50 and keeps an In Line rating on the shares.
Avantor price target raised to $13 from $11 at Deutsche Bank
Deutsche Bank raised the firm’s price target on Avantor (AVTR) to $13 from $11 and keeps a Hold rating on the shares.
Avantor price target raised to $15 from $8 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Avantor (AVTR) to $15 from $8 and keeps a Hold rating on the shares.
Avantor upgraded to Hold from Underperform at Jefferies
Jefferies upgraded Avantor (AVTR) to Hold from Underperform with a price target of $13, up from $7, following what the firm calls “a solid 2Q beat” and FY26 guidance raise.
Avantor Earnings Call Transcript: Q2 2026
Q2 results exceeded expectations with VWR returning to organic growth and BMP stabilizing. Strong free cash flow enabled debt reduction, and 2026 guidance for revenue and EPS was raised. Revival initiatives are driving operational improvements and sustainable momentum.
Avantor Earnings release: Q2 2026
Avantor released its Q2 2026 earnings on July 29, 2026, summarizing the period's financial results.
Avantor Slides: Q2 2026
Avantor has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 29, 2026.
Avantor Quarterly report: Q2 2026
Avantor has published its Q2 2026 quarterly earnings report on July 29, 2026.
Avantor reports Q2 adjusted EPS 21c, consensus 19c
Reports Q2 revenue $1.69B, consensus $1.61B. Emmanuel Ligner, President and Chief Executive Officer, said: “Our Revival program is strengthening how we serve our customers, leading to improved busines...
Avantor narrows FY26 adjusted EPS view to 80c-83c from 77c-83c, consensus 79c
Raises FY26 organic revenue view to down 0.5% to up 0.5% from down 2.5% to down 0.5%. Backs FY26 adjusted EBITDA margin view 14.8%-15.3%. Backs FY26 free cash flow view…
Avantor® Reports Second Quarter 2026 Results
Net sales of $1,692.3 million; increase of 0.5%; organic decline of 0.4% Net income of $38.1 million; Adjusted EBITDA of $254.3 million Diluted GAAP EPS of $0.06; adjusted EPS of $0.21 Operating cash ...
Avantor price target raised to $11 from $9 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Avantor (AVTR) to $11 from $9 and keeps a Hold rating on the shares. The firm adjusted targets in…
Avantor’s NuSil partners with The Population Council for HIV prevention
Avantor (AVTR) announced the expansion of a collaboration between its NuSil brand, a premier global manufacturer of high-purity silicones suitable for use in medical devices and drug-device combinatio...
Avantor's® NuSil® Brand Expands Partnership with the Population Council to Develop Long-Acting HIV Prevention Product
RADNOR, Pa., July 14, 2026 /PRNewswire/ -- Avantor (NYSE: AVTR), a leading global provider of mission-critical products and services to the life sciences and advanced technology industries, announced ...
Avantor price target raised to $11 from $9 at Citi
Citi analyst Patrick Donnelly raised the firm’s price target on Avantor (AVTR) to $11 from $9 and keeps a Neutral rating on the shares.
Avantor price target raised to $10.50 from $8 at Evercore ISI
Evercore ISI raised the firm’s price target on Avantor (AVTR) to $10.50 from $8 and keeps an In Line rating on the shares. The firm’s Q2 preview for MedTech, Life…
Avantor® to Report Second Quarter 2026 Earnings on Wednesday, July 29, 2026
RADNOR, Pa., July 1, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology indu...
Avantor resumed with a Market Perform at Bernstein
Bernstein resumed coverage of Avantor (AVTR) with a Market Perform rating and $10.50 price target following a return from maternity leave. “Many things” are going right for the life science…
Avantor price target raised to $8 from $7 at Barclays
Barclays raised the firm’s price target on Avantor (AVTR) to $8 from $7 and keeps an Underweight rating on the shares. The firm adjusted targets in the life science and…
Avantor assumed with Underperform at Wolfe Research
As previously reported, Wolfe Research downgraded Avantor (AVTR) to Underperform from Peer Perform with a $7 price target after assuming coverage of the stock. This rating “could have a short…
Avantor assumed with Underperform from Peer Perform at Wolfe Research
Wolfe Research downgraded Avantor (AVTR) to Underperform from Peer Perform with a $7 price target after assuming coverage of the name.
Avantor® Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
RADNOR, Pa., May 19, 2026 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology indu...